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The absence of relevant animal models of chronic hepatitis B virus (HBV) infection has hampered the
evaluation and development of therapeutic HBV vaccines. In this study, we generated a novel transgenic
mouse lineage that expresses human class I and II HLA molecules and the hepatitis B surface antigen
(HBsAg). HBsAg and hepatitis B core antigen (HBcAg) administered as plasmid DNAs and recombinant
proteins, either alone or in combination, were evaluated as therapeutic vaccine candidates in this mouse
model. Our results emphasize the importance of the route of administration in breaking HBsAg tolerance.
Although immunizing the transgenic mice with DNA encoding homologous HBsAg was sufﬁcient to
induce CD8þ T-cell responses, HBsAg from a heterologous subtype was required to induce a CD4þ T-cell
response. Importantly, only prime-boost immunization protocols that combined plasmid DNA injection
followed by protein injection induced the production of antibodies against the HBsAg expressed by the
transgenic mice.
& 2012 Elsevier Inc. All rights reserved.Introduction
Currently, more than 400 million individuals suffer from chronic
hepatitis B virus (HBV) infection worldwide. Sophisticated antiviral
treatments frequently confer substantial histological improvement,
but these lifelong treatments often elicit drug resistance. Conse-
quently, alternative approaches are needed to complement or
replace these antiviral treatments.
The humoral response to HBV is critical for protection from
infection and for long-term clearance of HBV. During acute hepatitis
and exacerbations of chronic hepatitis B, the strong responses against
HBV core antigen (HBcAg) in the form of anti-HBcAg antibodies
(anti-HBc) suggest important roles for these responses in controlling
HBV infection and achieving recovery (Ferrari et al., 1990). The
induction of neutralizing antibodies against HBV surface antigen
(HBsAg), reﬂects the clearance of the infection and provides protec-
tive immunity against subsequent HBV infection (Chisari, 1995;
Huang et al., 2006). Following activation of innate immunity, the
cellular response initiated by the T-cell response to viral antigens isll rights reserved.
ese des virus de l’he´patite B,
eur Roux, 75724, CEDEX 15,
. Bourgine).thought to play a key role in HBV clearance. HBV can be cleared by
cytolytic mechanisms (Maini et al., 2000; Moriyama et al., 1990) and
by non-cytolytic, cytokine-mediated mechanisms (Guidotti et al.,
1999). Patients resolving acute hepatitis display strong polyclonal
and multispeciﬁc CD4þ and CD8þ T-cell responses against nucleo-
capsid, polymerase and envelope HBV proteins. In contrast, T-cell
responses to HBV proteins are rarely detected in chronic HBV carriers
and this is thought to be due to T-cell exhaustion, to anergy or to
cytokine imbalance (Chisari, 1995; Ferrari et al., 1990; Rehermann
et al., 1995). An HBsAg-speciﬁc CD8þ T-cell response is undetectable
in patients chronically infected with HBV and suggests that excessive
serum HBsAg may function as a tolerogen during chronic infection.
Although very effective in preventive vaccination, HBV envelope
proteins generally do not induce a strong CD4þ T-cell response
during HBV infection (Bocher et al., 1999; Ferrari et al., 1990).
Nevertheless, the induction of HBV-speciﬁc CD4þ T-cells is regarded
to be an important component of any immunomodulatory therapy.
CD4þ T-cells contribute to the induction (Ridge et al., 1998) and
maintenance of antigen-speciﬁc CD8þ T-cells, they allow dendritic
cells to activate CD8þ effector T-cells (Ridge et al., 1998; Sigal et al.,
1999), and they provide help for activation and differentiation
of B-cells. Therapeutic vaccination has been proposed to over-
come the functional defects observed in the T-cell responses present
in chronically infected patients. The challenge of this strategy is to
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patients. Numerous clinical trials of therapeutic immunization using
conventional, prophylactic HBsAg-based vaccines have achieved
limited success and have underscored the need for further improve-
ments in the treatment of chronic HBV infection (reviewed in
(Michel et al., 2011)).
Due to the lack of in vitro models for chronic HBV infection,
HBV transgenic (Tg) mice are the most widely used models for
evaluating therapeutic strategies. Despite some limitations,
Tg mice expressing human HLA molecules are superior to wild-
type mice for testing vaccine candidates and for developing
therapeutic strategies based on the induction of T-cell responses
relevant to humans (Pajot et al., 2004; Rohrlich et al., 2003). HLA-A2
and HLA-DR1 Tg mice may facilitate improvements in therapeutic
strategies that require collaboration between HLA-restricted CD4þ
T-helper cells and HLA-restricted cytolytic CD8þ T-cells. In this
study, we generated a novel humanized HBsAg Tg mouse model as
a tool to assess different HBV antigens and different routes of
administration for their ability to inﬂuence T-cell responses and to
achieve successful therapeutic vaccination. We compared intrader-
mal, intranasal and intramuscular immunizations of DNA and
protein based on identical antigens.Results
‘‘Humanized’’ Tg mice expressing HBsAg
To evaluate the efﬁcacy of potential human therapeutic strate-
gies, we generated a novel Tg mouse lineage by crossing mice that
lack murine class I and II molecules but express transgenic human
HLA-A2 class I and HLA-DR1 class II molecules with an HBsAg-
C57BL/6 Tg mouse lineage (see Materials and Methods). The HBVFig. 1. Characterization of HBs-A2-DR1 mice. Relative expression of HBV genes was an
quantitative PCR (A). Results from 4 mice are expressed as mean value7SEM. (B) The
(black triangles) and 12 HBs-A2-DR1 mice (black circles) at different time points. Partic
and antibody titers were determined by serial end-point dilutions. (C) Western Blot anal
(1), HBsAg-C57BL/6 (2), A2-DR1 (3) and HBs-A2-DR1 (4) were detected either by rabbit
small (S), middle (M) and large (L) envelope proteins of HBV are indicated. M corespond
heavy and light chains of the mouse immunoglobulins. (D) Representative histogram
C57BL/6 (gray ﬁll) mice stained for surface molecules with PE-conjugated anti-HLA-A2transgene consisted of a copy of the HBV genome (ayw subtype)
with the core gene deleted (Babinet et al., 1985). Due to the
heterozygous status of the HBV transgene, only 50% of the offspring
express the HBV transgene and are therefore referred to as either
HBs-A2-DR1 or A2-DR1 mice, depending on whether or not they
produce HBsAg. As in the parental HBsAg-C57BL/6 lineage, liver-
speciﬁc synthesis of the HBV envelope proteins in the HBs-A2-DR1
mice began before birth. Quantitative measurement of liver HBV
mRNA revealed similar levels of expression in the two lineages
(Fig. 1A). The HBV proteins synthesized by the hepatocytes
self-assembled into HBsAg particles that were secreted into the
sera of mice (Fig. 1B). Western blot analysis and staining with an
anti-HBs antibody showed that HBsAg particles contain the small
(S), middle (preS2þS) and large (preS1þpreS2þS) envelope pro-
teins in both glycosylated and non glycosylated forms (Heermann
et al., 1984) (Fig. 1C). To discriminate between dimers of small
proteins and large envelope proteins, an anti-preS1 antibody
speciﬁc for the large protein was used in western blot analysis
(Fig. 1C, right panel). Neither differences in the concentration of the
particles (Fig. 1B) nor in the ratio of the different proteins were
observed in sera from HBs-A2-DR1 and parental HBsAg-C57BL/6
mice (Fig. 1C). Despite the absence of transgene expression in the
thymus (data not shown), HBs-A2-DR1mice were tolerant to HBsAg
because no antibodies or T-cell responses directed to HBsAg could be
detected, even after non-speciﬁc stimulation (Fig. 1B and data not
shown). Nevertheless, serum HBsAg levels in the mice decreased
slightly over a six-month period (Fig. 1B). This phenomenon was
also observed in the parental lineage and has been attributed to
hormonal regulation (Farza et al., 1987). Using ﬂow cytometry, we
determined that the HLA-A2 and HLA-DR1 molecules were
expressed by spleen cells from the humanized Tg mice but not by
cells from the parental HBsAg-C57BL/6 mice (Fig. 1D). In addition,
the mean ﬂuorescence intensities of the A2-DR1 and HBs-A2-DR1alyzed in the liver from six week-old HBsAg-C57/BL6 and HBs-A2-DR1 mice by RT
HBsAg concentration (in ng/ml) was evaluated in the sera of 12 HBsAg-C57/BL6
les of HBsAg ayw subtype were used to detect anti-HBs antibodies (empty circles)
ysis of HBsAg particles present in mouse sera. HBV envelope proteins from C57/BL6
anti-HBs (left) or mouse anti-preS1 (right) antibodies. Bands corresponding to the
s to protein size markers (75, 50, 37, 25, 20 kDa from the top). Arrows indicate the
s for total splenocytes from A2-DR1 (black lines), HBs-A2-DR1 (dotted lines) and
(left) and APC-conjugated anti-HLA-DR (right) monoclonal antibodies.
Fig. 2. Induction of T-cell responses in mice after pCMV-S2.S ayw immunization.
Time schedule of immunization and analysis is presented on the top of the ﬁgure.
Groups of A2-DR1 (white bars) and HBs-A2-DR1 (black bars) mice were immu-
nized by i.m. injection of pCMV-S2.S ayw into cardiotoxin-treated tibialis anterior
muscles on days 0 and 21. Splenocytes were collected three weeks after the
second immunization and HLA-A2- or HLA-DR1-restricted (underlined) HBs-
derived peptides from the ayw subtype were used to stimulate the splenocytes
ex vivo. (A) Quantiﬁcation of IFN-g-secreting T-cells by ELISPOT assay. Each bar
represents the mean value7SEM of IFN-g-secreting T-cells per million spleno-
cytes (n¼3 to 13 mice). Identical numbers of mice were used to determine the
statistical signiﬁcance of differences between groups by the Mann-Whitney U test.
n, po0.05; nn, po0.01. (B) Characterization of the IFN-g-producing T-cell subsets
by depletion experiments in A2-DR1 mice. Representative ELISPOT assays per-
formed on CD4-depleted T-cells (striped bar), CD8-depleted T-cells (gray bars), or
undepleted splenocytes (empty bars).
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transgene did not hamper the expression of the HLA molecules.
Immune response to homologous ayw HBsAg subtype after
DNA-based immunization
To ensure that the substitution of the murine MHC molecules
by their human counterparts did not prevent an immune
response to HBsAg, we evaluated the immune response induced
by i.m. injections of the pCMV-S2.S ayw plasmid DNA in A2-DR1
mice (Fig. 2). The pCMV-S2.S expresses the small and the middle
HBV envelope proteins. The resulting particles contain about 30%
of middle proteins ((Michel et al., 1995) and data not shown). In
ex vivo stimulation assays, splenocytes from immunized A2-DR1
mice secreted IFN-g following stimulation with all HBsAg
ayw-derived peptides tested (Table 1 and Fig. 2A). Depletion
of speciﬁc T-cells subsets (Fig. 2B) revealed that some peptides
(pep) were able to activate both CD4þ and CD8þ T-cells
(pep 200–214, pep 337–357 and pep 348–357) whereas others
activated only CD4þ T-cells (pep 114–128) or only CD8þ T cells
(pep 183–191). IFN-g production by CD4þ T cells after stimula-
tion with pep 337–357 ayw was conﬁrmed by intracellular staining
(data not shown). IFN-g-producing T-cells were also detected follow-
ing plasmid DNA immunization of HBs-A2-DR1 mice (Fig. 2A).
HLA-A2 restricted peptides (see Table) were able to trigger similar
levels of IFN-g secretion by HBs-A2-DR1 CD8þ T-cells and
by A2-DR1 CD8þ T-cells. In contrast, following stimulation with
HLA-DR1 restricted peptides 114–128 and 200–214, the number of
IFN-g-producing T-cells from immunized HBs-A2-DR1 mice was
signiﬁcantly lower than the number found in immunized A2-DR1
mice. Further analysis revealed that following stimulation with
HLA-DR1-restricted peptides, no IFN-g-secreting CD4þ T-cells could
be detected in HBs-A2-DR1 mice by intracellular staining (data not
shown). These results indicated that DNA immunization with a
plasmid encoding the HBsAg ayw subtype in HBs-A2-DR1 mice
expressing the same HBsAg subtype was able to generate a
CD8þ T-cell response identical to the one obtained in immunized
A2-DR1 mice. However, the HBs-speciﬁc CD4þ T-cell response was
undetectable in immunized HBs-A2-DR1 mice.
Cellular response after immunization with a heterologous adw HBsAg
subtype combined with HBcAg
Results obtained in HBs-A2-DR1 mice underlined a defect in the
CD4þ T-cell response toward the ayw HBsAg subtype expressed by
these mice. We therefore investigated whether DNA immunization
of HBs-A2-DR1mice with a plasmid encoding the heterologous adw
HBsAg subtype could elicit a cross-reactive CD4þ T-cell immune
response against the transgenic ayw HBsAg produced by the mice.
To potentiate the immunization and because HBcAg may act as a
T-cell-dependent and -independent antigen (Milich and McLachlan,
1986), HBs-A2-DR1 and A2-DR1 mice were immunized twice
with a combination of pCMV-S2.S adw encoding the adw variant
of HBsAg and pMasCore encoding the capsid protein of HBV. Two
weeks after the ﬁnal immunization, splenocytes were harvested
and stimulated ex vivo with libraries of HBV core and envelope
peptides or with the HBcAg. High frequencies of HBcAg- and
HBsAg-speciﬁc IFN-g-producing cells were detected in the spleens
of immunized mice, which indicated that the DNA immuniza-
tion was successful (Fig. 3A). The frequency and speciﬁcity of
HBcAg-speciﬁc IFN-g-producing cells were comparable in the two
lineages. Stimulation with HBcAg particles or the HBcAg peptide
pool C1–55 elicited similar numbers of IFN-g-producing cells in
each lineage suggesting that the T-cell response was focused on the
N-terminal part of the capsid protein. The pCMV-S2.S adw plasmid
also primed HBsAg-speciﬁc responses that were mainly directedto pools S164–218 and S338–389 in both lineages. Conversely, no
IFN-g secretion was observed after stimulation with the preS2 ayw
set of peptides indicating that either the preS2 adw region was not
immunogenic or the induced T-cell response was not detectable
with the preS2 ayw peptides used to stimulate the cells.
Table 1
HLA-restriction and speciﬁcity of HBV envelope-derived epitopes.
Residuea Amino acid
sequenceb
HLA-restriction Subtypec References
114–128 TTFHQTLQDPRVRGL DR1 ayw Pajot et al., 2006
183–191 FLLTRILTI A2 adw/ayw Chisari, 1995
200–214 TSLNFLGGTTVCLGQ DR1 ayw Pajot et al., 2006
TSLNFLGGSPVCLGQ DR1 adw Pajot et al., 2006
204–212 FLGGTTVCL A2 ayw Chisari, 1995
FLGGTPVCL A2 adw Chisari, 1995
335–343 WLSLLVPFV A2 adw/ayw Nayersina et al., 1993
337–357 SLLVPFVQWFVGLSPTVWLSV DR1 ayw Pajot et al., 2006
348–357 GLSPTVWLS A2 adw/ayw Nayersina et al., 1993
370–379 SILSPFLPLL A2 ayw Chisari, 1995
a Positions of peptides on the HBV envelope protein are indicated starting from the ﬁrst methionine of the PreS1 region in the
HBV ayw sequence.
b Amino acid sequence of the peptides.
c Subtype of HBsAg.
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IFN-g, we stained the cells for intracellular IFN-g. CD8þ T-cell
responses were detected following stimulation with all reactive
peptide pools and no signiﬁcant differences were observed
between the two lineages (Fig. 3B, left). The most remarkable
T-cell responses were observed after stimulation with peptide
pool S164–218, which contained the S183–191 and S204–212
CD8þ T-cell epitopes and the S200–214 CD4þ T-cell epitope.
Using individual peptides, we found that immunization of
HBs-A2-DR1 mice with the pCMV-S2.S adw induced a CD8þ
T-cell response to peptide S200–214 adw and, more precisely, to
the A2-restricted epitope S204–212 adw (Fig. 3C, upper panel).
We next examined whether the pCMV-S2.S adw-primed CD8þ
T-cells were able to cross-react with the ayw epitope of the HBsAg
that was constitutively produced by the HBs-A2-DR1 mice. The
primed CD8þ T-cells showed no cross-reactive recognition of the
S204–212 ayw epitope (Fig. 3C, upper panel). We detected IFN-g-
producing CD4þ T-cells in A2-DR1 mouse splenocytes stimulated
with pools of HBcAg- or HBsAg-derived peptides (Fig. 3B, right). In
HBs-A2-DR1 mice, and in contrast to what we observed for the
CD8þ T-cell response, a CD4þ T-cell response was detectable only
after stimulation with pool S164–218 (Fig. 3B, right). Stimulation
with individual peptides indicated that this response was directed
to the HLA-DR1-derived peptide S200–214 from the adw subtype
(Fig. 3C, lower panel). These results indicate that DNA immuniza-
tion with an HBsAg-encoding plasmid from a heterologous subtype
is able to generate a CD4þ T-cell response in HBs-A2-DR1 mice.
Adding core antigen to the immunization did not improve the
response to HBsAg as no cross-reactive responses to ayw peptides
could be detected.
Humoral response after immunization with a heterologous
adw HBsAg subtype combined with HBcAg
Since HBcAg is also a potent B-cell activator, even in the
absence of adjuvant (Milich and McLachlan, 1986), we investi-
gated the antibody responses induced in HBs-A2-DR1 and A2-DR1
mice after two i.m. injections of the pCMV-S2.S adw/pMasCore
DNA combination. The immunizations achieved identical anti-
HBc antibodies titers in both lineages (Fig. 4A). This result was
expected since none of the humanized Tg mice expressed HBcAg.
To deﬁne precisely the speciﬁcity of the anti-HBs response
produced by the immunization, we used HBsAg adw particles
and HBsAg ayw particles to detect the responses to the different
HBsAg determinants (i.e., the anti-‘a’, ‘d’ and ‘w’ responses).
Whereas ayw particles could only detect responses to the ‘a’and ‘w’ determinants, the adw particles could detect responses to
the ‘a’, ‘d’, and ‘w’ determinants in the serum of mice immunized
with pCMV-S2.S adw. We detected low levels of anti-HBs anti-
bodies in each lineage that were primarily directed against the ‘d’
determinant since the HBsAg ayw particles coated on the solid
phase detected only very low anti-HBs levels in the serum of mice
(Fig. 4A). Of note, the anti-HBs titers in the A2-DR1 mice were
signiﬁcantly higher than those in the HBs-A2-DR1 mice.
As DNA immunization induces a weaker humoral response than
protein immunization, and in order to increase anti-HBs antibody
production, we immunized the two mouse lineages with protein
antigens using Nasvac, a formulation containing HBcAg and HBsAg
adw proteins without adjuvant (Aguilar et al., 2004). We adminis-
tered the proteins by the i.d. and i.n. routes. It has been reported that
immunization by the i.d. route can achieve higher antibody titers
than those produced by the i.m. route (Endmann et al., 2010) and that
the use of nasal immunization can also improve antigen uptake due
to the numerous antigen-sampling dendritic cells located in the nasal
mucosa (Kallenius et al., 2007). Three injections with the formulation
were highly immunogenic in A2-DR1 and HBs-A2-DR1 mice espe-
cially with respect to anti-HBc antibodies (Fig. 4B). Nasvac immuni-
zation generated tenfold more anti-HBc antibodies than the DNA
injections (p¼0.011 for A2-DR1 mice; p¼0.002 for HBs-A2-DR1
mice). In contrast, mice immunized by either method produced
similar anti-HBs antibody levels, whether the antigens were adminis-
tered as DNA or as puriﬁed proteins without adjuvant. Once again,
anti-HBs antibody titers were signiﬁcantly higher in A2-DR1 mice
than in HBs-A2-DR1 mice (p¼0.0009). These antibodies were mainly
directed against the ‘d’ determinant in A2-DR1 mice and were not
detectable in HBs-A2-DR1 mice. This result suggested that the anti-
HBs antibodies in the HBs-A2-DR1 mice were complexed in vivowith
the circulating HBsAg particles produced by the mice. To test this
hypothesis, we determined if the induced humoral response in the
immunized mice impacted the serum HBsAg concentration in HBs-
A2-DR1 mice (Fig. 4C). We detected a signiﬁcant decrease in HBsAg
levels in sera collected three weeks after the last i.d and i.n. protein
injections but not after the i.m. DNA injections. These results
indicated that immunization strategies that combine core antigen
with a heterologous HBsAg subtype are able to induce anti-HBs
antibodies that recognize the HBsAg particles present in HBs-A2-
DR1 mice.
Prime-boost strategy
To optimize the immunogenic potential of the HBV DNAs
and proteins, we induced cellular and humoral responses by
Fig. 3. Speciﬁcity of T-cell responses following immunization with DNAs encoding
a heterologous HBsAg adw subtype and HBcAg. Ex vivo ELISPOT assay (A) or
intracellular staining (B and C) performed on A2-DR1 (white bars) and HBs-A2-
DR1 (black bars) splenocytes from mice immunized by i.m. injections with pCMV-
S2.S adw and pMasCore on days 0 and 21. Two weeks after the second injection,
pools of 15-mer peptides covering either the entire HBcAg (C1–55; C46–95; C86–
140 and C131–185), the preS2 domain, HBsAg (S164–218; S213–286; S285–357
and S338–389) or the HBcAg protein were used to stimulate splenocytes.
(B) Spleen cells were analyzed for CD8þ T-cells (left panel) or CD4þ T-cells
(right panel) producing intracellular IFN-g following stimulation with peptide
pools C1–55, S164–218 and S338–389. Data are the mean7SEM for 8 mice per
group. (C) Representative FACS plots of intracellular staining used to deﬁne the
percentages of the IFN-g-secreting T-cell subsets present in the spleens of
immunized HBs-A2-DR1 mice. Peptides used to stimulate the splenocytes are
indicated. Values in the squares are the percentages of IFN-gþ cells among the
CD8þ (upper panels) or CD4þ (lower panels) T-cells.
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with two injections of pCMV-S2.S adw/pMasCore DNAs (i.m., or
i.d and i.n.) followed by three i.d and i.n. doses of Nasvac (Fig. 5A
and C) or with three treatments of the Nasvac formulation (i.d and
i.n.) followed by two i.m. injections of the HBV DNAs (Fig. 5B). As
controls, we injected mice with PBS by the same routes. We then
determined the HBsAg levels in sera collected three weeks after
each immunization. After the second intramuscular injection of
the DNAs or PBS, the HBsAg levels were not signiﬁcantly different
from preimmune levels (Fig. 5A, compare weeks 0 and 6), which
conﬁrmed the results shown in Fig. 4C. In contrast, the HBsAglevels had decreased signiﬁcantly after three i.d. and i.n. injec-
tions of proteins (Fig. 5B, weeks 9 and 12). However, a similar
decline was also observed in the PBS-injected group. This phe-
nomenon was observed in all vaccination strategies only after i.d.
and i.n. injections of PBS, suggesting that repeated i.d. and i.n.
injections exerted a non-speciﬁc effect on HBsAg levels. Never-
theless, when the DNAs were injected i.m. prior to protein immu-
nization, serum HBsAg levels decreased markedly and speciﬁcally
(73% decrease) after the ﬁrst boost of protein (Fig. 5A week 9,
po0.001) and this decrease persisted up to week 15. In contrast,
DNA boosts did not enhance the decrease in HBsAg levels in the
sera of mice that were ﬁrst immunized with proteins (Fig. 5B).
We therefore evaluated the DNA prime/protein boost strategy
using DNAs and recombinant proteins that were given only by the i.d
and i.n. route (Fig. 5C). Due to high variability in the groups at week
0, no signiﬁcant decreases in HBsAg levels compared to preimmune
levels were detected. Nevertheless, intergroup comparisons revealed
that the HBsAg titers in mice from the DNA-primed group were
signiﬁcantly lower than those from the PBS-injected control group,
starting at three weeks after the second DNA immunization. This
effect was still boosted after two Nasvac injections and corresponded
at week 12 to a 62% decrease in the HBsAg levels compared to
preimmune levels. These results indicate that i.d and i.n injections of
the DNAs were also able to decrease serum HBsAg levels in HBs-A2-
DR1 mice. To assess the impact of DNA prime-protein boost
strategies on intrahepatic HBV mRNA levels, livers from immunized
mice were taken at week 12. Quantitative RT-PCR showed that the
level of HBV mRNAs was proportional to the HBsAg concentration in
sera (r value determined by the Spearman correlation test, 0.83;
Po0.0001) indicating that immunizations had modulated the HBV
mRNA expression.
At the end of the immunization protocols, we also determined the
anti-HBs humoral responses induced by the three prime-boost
strategies (Fig. 5D). Despite HBsAg titers in the PBS-injected groups
that were lower at week 15 than the preimmune levels, no anti-HBs
antibodies were detected in any of the PBS-injected groups. In
contrast, anti-HBs antibodies were detected in all three immunized
groups. After the DNA prime/protein boost strategy, anti-HBs anti-
body titers at week 15 were between 10 and 100 times higher than
after the primes only (compare Figs. 5D and 4A). The most effective
protocol consisted of intramuscular DNA injections followed by i.d
and i.n Nasvac immunizations. This was the only protocol in which
anti-HBs antibodies were detected using the ayw particles as the
capture antigen. Although our assay was unable to distinguish
between an anti-‘a’ or an anti-‘y’ response, this result demonstrated
the presence of antibodies able to recognize HBsAg ayw particles
similar to those produced by the HBs-A2-DR1 mice. This was not the
case with the protocol that used only the i.d and i.n. routes, which
induced only anti-‘d’ antibodies. Altogether, these results show that
priming with DNA immunizations followed by boosts with protein
antigens were more efﬁcient in reducing HBsAg levels in HBs-A2-
DR1 mice than immunization protocols that primed with protein
and boosted with DNA. Furthermore, only i.m. DNA injections were
able to elicit antibodies speciﬁc for the HBsAg expressed by the HBs-
A2-DR1 mice.Discussion
Few animal models for chronic HBV infection exist currently.
Although chimpanzees can be infected and may develop chronic
disease, these animals are not readily available or accessible. To
evaluate the potential beneﬁts of therapeutic HBV vaccines, surro-
gate models that effectively reproduce the characteristics of the
chronic HBV infection are needed. Most existing models rely on Tg
mice that replicate the virus or express HBV proteins. However, since
Fig. 4. Antibody response in immunized mice. Groups of A2-DR1 (empty symbols) and HBs-A2-DR1 (black symbols) mice were immunized twice by i.m. injection of
pCMV-S2.S and pMasCore DNAs (A) or three times by i.d. and i.n. injection of Nasvac proteins (B). Three weeks after the last injection, antibodies in sera were quantiﬁed by
ELISA. HBV core particles (HBc) were used to detect anti-capsid antibodies and particles of HBsAg adw (identical to the injected antigens) and HBsAg ayw (similar to
particles expressed by the HBs-A2-DR1 mice) were used to detect anti-envelope antibodies. The antigens used for detection are indicated on the x axis above the name of
the mouse lineage. Antibody titers were determined by serial end-point dilutions. The titer was deﬁned as the highest serum dilution that resulted in an absorbance value
two times greater than that of non-immune serum. (C) HBsAg concentration (ng/ml) in the sera of HBs-A2-DR1 mice was determined before (Pre) and three weeks after the
last injection (Post) of DNAs or proteins (Nasvac). Data show the mean values7SEM. Signiﬁcant p values are indicated. NS: not signiﬁcant.
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responses, optimal models must also allow these responses to be
considered in humans. In this study, we have generated a novel Tg
mouse lineage that meets these criteria. As in chronic HBV carriers,
these mice express large amounts of HBsAg, which is known to
induce tolerance. They also express the human MHC class I and II
molecules in the absence of murine MHC molecules. This allows the
detection of immune responses that are potentially identical to those
observed in HLA-A2 and HLA-DR1 individuals. Indeed, we showed
that immunizing A2-DR1 mice with a plasmid encoding HBsAg
induced a high frequency of IFN-g-secreting T-cells in the periphery.
These cells had speciﬁcity for endogenously processed HBV peptides
and they exhibited recognition speciﬁcities similar to those that arise
during self-limited infection or vaccination in humans (Chisari, 1995;
Pajot et al., 2006). By contrast, no CD4þ T-cell responses could be
detected in the HBs-A2-DR1 mice, which correlated with the situa-
tion in human chronic infection where a CD8þ T-cell response is
found in the absence of a detectable CD4þ T-cell response (Urbani
et al., 2005). Immune responses induced in this well-deﬁned model
system can provide useful insight into the CD4þ T-cell reactivities
required to resolve chronic HBV infection. So far, therapeutic HBsAg-
based vaccination of chronically infected patients has been unable to
entirely control the infection (Michel et al., 2011). Therefore, our Tg
mice represent a valuable model for evaluating the efﬁcacy of pro-
spective immunogens for therapeutic vaccination. HBcAg-speciﬁcCD4þ T-cell responses are detectable in patients during acute
infection and are probably essential for controlling viremia. More-
over, HBcAg can function as both a T-cell-independent and a T-cell-
dependent antigen (Milich and McLachlan, 1986) and HBcAg-speciﬁc
CD4þ T-cells can sustain anti-core and anti-envelope antibody
production (Milich et al., 1987). Similarly, the generation of
CD4þ T-cells speciﬁc for heterologous HBsAg adw epitopes, which
is induced by the endogenous (DNA immunization) and exogenous
(protein immunization) processing of antigens, may facilitate the
priming of CD8þ T-cells and anti-HBsAg antibody responses in
HBs-A2-DR1 mice. This has been shown to be important for the
CD8þ T-cell response in a therapeutic approach that used variants
expressing cross-reactive CTL epitopes (Schirmbeck et al., 2003).
Anti-HBs antibodies are considered to be the predominant factor
in preventing HBV infection due to their capacity to eliminate
circulating viral particles. Thus, the induction of a humoral response
in chronic HBV infection could eliminate the virus and reduce the
established tolerance to HBsAg. The use of a single injection route
induced different anti-HBs antibody responses in our two mouse
lineages. The anti-HBs antibody response in HBs-A2-DR1 mice, which
was characterized with adw particles to allow detection of the
response to the heterologous ‘d’ epitope, was less intense than the
one achieved in A2-DR1 mice. This weaker reactivity could be
ascribed to lower antibody production by anergic B-cells. However,
the humoral response to HBcAg was comparable in both lineages,
Fig. 5. Titration of HBsAg and anti-HBs antibodies in the sera of HBs-A2-DR1 mice following prime/boost immunization. Groups of 8 (A, C) and 5 (B) HBs-A2-DR1 mice
were immunized either twice by i.m. injections of the pCMV-S2.S adw/pMasCore DNAs and three times by i.d and i.n. injections of Nasvac proteins (A, B) or ﬁve times by i.d
and i.n injection of DNAs and Nasvac proteins (C) as indicated under each panel. PBS-injected HBs-A2-DR1 mice were used as controls. Sera were collected every three
weeks and evaluated for HBsAg concentration (ng/ml). (D) Three weeks after the last injection, antibodies in the sera of mice immunized by the protocols described in A, B,
C were quantiﬁed by ELISA as in Fig. 4. Results are given as mean values7SEM. For multiple comparisons, an ANOVA followed by the Friedman test and Dunn’s Post-test
were used to determine signiﬁcant differences. The Mann-Whitney U test was used for intergroup comparisons and stars indicate a signiﬁcant difference between
compared groups. n, po0.05; nn, po0.01; nnn, po0.001.
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bodies against foreign antigens at levels identical to those produced
by A2-DR1 mice. Nevertheless, we cannot exclude the possibility that
some of the antibodies produced by the immunized HBs-A2-DR1
mice were directed against additional adw antigenic determinants
that were recognizable on the circulating ayw particles but not the
ayw antigen coated on the solid phase.
Since the HBsAg produced in vivo by the HBs-A2-DR1 mice can
adsorb a fraction of the antibodies generated by immunization, ﬁne
analysis of the speciﬁcities of the antibody response remains difﬁcult.
However, the decrease in HBsAg titers that occurred in response to
the prime-boost protocol suggests that the mice produced cross-
reactive anti-HBs antibodies able to complex with circulating HBsAg.
Of note, anti-subtype ‘y’ antibodies were produced only after i.m.
DNA injection, revealing that this route of immunization was
important for subverting B-cell tolerance.
Creating a successful therapeutic vaccine requires that vaccine
formulation and delivery routes be optimized. Recent studies
have suggested that a heterologous prime-boost vaccination
approach, in which the same antigen is delivered sequentially
by different types of vaccines, was very effective at eliciting
enhanced and broad humoral and cellular immune responses
(Lu, 2009). Such heterologous regimens can be effective when
clearances of viral particles and of virus-infected cells are both
required to resolve infection. Our evaluation of these DNA and
protein immunogens in a prime-boost strategy revealed differ-
ences in the resulting immune response that should be taken intoconsideration to when optimizing therapeutic vaccination strate-
gies. We showed that the routes of DNA immunization generated
different humoral responses, probably due to the presence of
different types of antigen presenting cells in skin, mucosa and
muscle. Further studies should be conducted to evaluate whether
prime-boost regimens generate broader T-cell responses than
those produced by prime-only procedures. Of note, a decrease
in HBsAg levels was observed following i.d and i.n. injections of
PBS. Despite the injection of small volumes, the i.d and i.n. routes
of immunizations may generate tissue damage. We speculate that
following tissue damage, damage-associated molecular patterns
activated by endogenous intracellular molecules released by
necrotic cells and/or extracellular matrix molecules could lead
to Toll-like receptors (TLR) activation that, in turn, induces
inﬂammatory gene expression (Piccinini and Midwood, 2010).
Necrotic cells have been also found to cause dendritic cell
maturation in a TLR2 dependent manner. Recruitment of
antigen-nonspeciﬁc inﬂammatory cells and production of cyto-
kines could therefore modulate the HBV gene expression as it
has been already shown in an HBV transgenic mouse model
(Chisari, 1995).
Immunization with proteins usually requires that potentially
toxic adjuvants be delivered with the immunizing component of
the vaccine. In this study, we showed that low doses of protein
antigens delivered without adjuvant induced potent polyclonal
and multispeciﬁc cellular and humoral responses and that they
also reduced the levels of circulating HBsAg when combined with
M. Bourgine et al. / Virology 430 (2012) 10–19 17intramuscular injections of DNAs. The Nasvac and plasmid DNA
used in this study are currently being manufactured and have
demonstrated their safety in the development of vaccines
(Betancourt et al., 2007; Mancini-Bourgine et al., 2004). In the
setting of therapeutic vaccination, where multiple vaccine doses
are often required, an effective adjuvant-free vaccine is preferred.
The capacity of a candidate vaccine to generate potent polyclonal
and multispeciﬁc cellular and humoral responses is an important
feature for controlling chronic hepatitis B infection.
Taken together, our data show that immunization with
HBV antigens can generate B- and T-cell responses even in a
tolerogenic context and demonstrate that HBs-A2-DR1 mice
represent a relevant model for preclinical evaluations of thera-
peutic vaccines.Materials and methods
Transgenic mice
A novel Tg mouse lineage was obtained by intercrossing HLA-
An0201þ /þ/HLA-DR1þ /þdouble-transgenic H-2 class I (b2m0/0)-/
class II (IAb0/0)–KO mice (Pajot et al., 2004) and HBsAgþ /0/C57BL/
6 mice (Babinet et al., 1985). Progeny were screened by PCR for
the presence of the HLA-An0201 and HLA-DR1 transgenes until
HBsAgþ /0/HLA- An0201þ /þ/HLA-DR1þ /þ transgenic H-2 class I
(b2m0/0)-/class II (IAb0/0)–KO animals were obtained. The homo-
zygous status of HLA-An0201 and HLA-DR1 transgenes was
conﬁrmed by the presence of both transgenes in the progeny
obtained by crossing the novel Tg mice with C57BL/6 mice. The
HBsAg/HLA-A2/HLA-DR1 Tg mice express chimeric HLA-A2 MHC
class I, HLA-DR1 MHC class II molecules and HBV envelope
proteins from genotype D carrying the HBsAg of subtype ayw in
the liver, which are secreted and present in serum throughout the
animal’s lifetime (see Fig. 1). Due to the heterozygous status of
the HBV transgene, only 50% of the offspring express the HBV
transgene and are therefore referred to as either HBs-A2-DR1 or A2-
DR1 mice, depending on whether or not they produce HBsAg.
All mice were six to nine weeks of age at the ﬁrst administra-
tion and were maintained at the Institut Pasteur animal facility
under speciﬁc-pathogen-free conditions. All protocols were
reviewed by the Institut Pasteur competent authority for com-
pliance with the French and European regulations on Animal
Welfare and with Public Health Service recommendations.DNA vectors and recombinant antigens
Plasmid DNAswere endotoxin-free andmanufactured by Plasmid-
Factory (Germany). The pCMV-S2.S ayw and adw plasmids encode
the preS2 and S domains of the ayw or adw subtype of HBsAg,
respectively, and their expression is controlled by the cytomegalo-
virus immediate early gene promoter (Michel et al., 1995). The
pMasCore plasmid (a kind gift of H. L. Davis, Coley Pharmaceutical
Group) encodes the HBV capsid carrying the hepatitis B core antigen
(HBcAg) of the adw subtype.
The recombinant HBsAg subtype adw was expressed by and
puriﬁed from Pichia pastoris yeast cells and was produced at over
95% purity at the production facilities of the Center for Genetic
Engineering and Biotechnology (CIGB, Havana, Cuba), as a compo-
nent of the commercial HBV prophylactic vaccine Heberbiovac-HB.
The entire recombinant HBcAg particle of 183 amino acids was
expressed in Escherichia coli and obtained with a purity of 495%.
The Nasvac formulation, containing both antigens at a concentra-
tion of 100 mg/ml, was obtained by simple mixture in phosphate-
buffered saline (PBS) (Aguilar et al., 2004).Protein analysis and immune staining of HBsAg particles
Pooled mouse sera were clariﬁed and subjected to ultracentri-
fugation on a 30% sucrose cushion in PBS for 4 h at 40,000 rpm.
Pellets were resuspended in an appropriate volume of Laemmli
buffer containing 2% b-mercaptoethanol, and subjected to protein
electrophoresis on NuPAGE 4–12% Bis TRIS gels (Invitrogen). Pro-
teins were transferred onto nitrocellulose membranes (Biorad), and
probed with speciﬁc anti-S and anti-preS1 antibodies. Membranes
were then blocked with 3% nonfat milk dissolved in PBS-0.05%
Tween 20 for 1 h and incubated overnight with a rabbit anti-S
(R247; 1:500 dilution (Jenna and Sureau, 1999)) or a mouse anti-
preS1 (Mab 18/7; 4 mg/ml kindly provided by W.H. Gerlich, Institut
fu¨r Med. Virologie, Giessen, Germany) antibodies. After four washes
in PBS-0.05% Tween 20 for 15 min, membranes were incubated for
35 min with appropriate secondary antibodies labeled with IRDye
(Rockland Immunochemicals), with gentle shaking and protection
from light. Fluorescent immunoblot images were then acquired and
quantiﬁed by using an Odyssey scanner and the Odyssey 1.2 soft-
ware (Li-Cor Biosciences).
RNA isolation and quantiﬁcation of liver HBV mRNAs
Total RNA was prepared from liver samples with TRIzol reagent
and TURBO DNA-free reagent (Life Technologies). RNA (5 mg) was
retrotranscribed using oligo(dT)18 primers (Fermentas) and M-MLV
Reverse Transcriptase (Life Technologies). For quantitative PCR, HBV
(forward 50–GCTTTCACTTTCTCGCCAAC-30, reverse 50–GAGTTCCG-
CAGTATGGATCG-30) and HPRT (forward 50–ATGCCGAGGATTTG-
GAAAAA-30, reverse 30–ACAATGTGATGGCCTCCCA-50) primers were
used. Samples were prepared in triplicates by addition of 5 ng of
cDNA to HBV and HPRT primers and SYBR Green PCR Master Mix
(Applied Biosystems). Quantitative PCR was carried out on an ABI
Prism 7900HT Sequence Detection System (Applied Biosystems)
using a standard PCR protocol (denaturation at 95 1C, annealing and
extension at 60 1C). For data analysis, gene expression values were
determined using the 2DCT method (Schmittgen and Livak, 2008),
where DCT¼CT (HBV primers)  CT (HPRT primers), and were
reported as arbitrary units.
Immunization protocols
Groups (ﬁve to ten female mice/group) were immunized by
different routes, including bilateral intramuscular (i.m.) injection
into cardiotoxin-treated tibialis anterior muscles as previously
described (Michel et al., 1995) or intranasal (i.n.) and intradermal
(i.d.) inoculations. All injections were carried out under anesthe-
sia attained by administering 100 mL ketamine (12.5 mg/mL) and
xylazine (1.25 mg/mL). Mice were immunized two times with
DNAs and three times with recombinant antigens and the
immunizations were given three weeks apart. Products were
either dispensed slowly into both nostrils (50 ml) using a pipette
tip for i.n. administration or injected into both ear pinnae (50 ml)
for i.d. injection. A total of 100 mg of DNAs or 10 mg of proteins in
a total volume of 100 ml was used for each injection.
Synthetic peptides
Four distinct sets of synthetic peptides were used in this study: a
pool of peptides containing the known HLA-A2- and HLA-DR1-
restricted peptides within the preS2 and S domains of the HBV
envelope proteins (see Table 1); a pool of ten 15-mer peptides
spanning the entire preS2 region of HBV envelope subtype ayw; a
pool of 9- to 15-mer peptides spanning the entire region of the HBV
envelope subtypes ayw and adwwere divided into four sets of eleven
peptides (S164–218, S213–286, S285–357 and S338–389); and a pool
M. Bourgine et al. / Virology 430 (2012) 10–1918of 36 overlapping 15-mer HBV core peptides comprising the whole
HBcAg of the adw subtype. This HBcAg pool was divided into four sets
of nine peptides (C1–55, C46–95, C86–140, and C131–185).
Synthetic peptides were purchased from Polypeptide Group
(Strasbourg) and were used at a ﬁnal concentration of 1 mM.
Peptide purity was480%. Peptides were dissolved in RPMI or
DMSO at a concentration of 10 mg/ml and diluted to 1–2 mg/ml
with culture medium before use.
Detection of serological parameters by ELISA
Serum samples were repeatedly obtained from vaccine-immu-
nized mice or placebo-inoculated control mice by retro-orbital
puncture using heparinized glass pipettes at different time points
post-injection. ELISA was used to quantify the antibodies in the
sera before and after immunization. For antibody determination,
serial dilutions of sera were added to antigen-coated wells (1 mg/ml)
and bound antibodies were detected by staining with anti-mouse
horseradish peroxidase (Life Sciences). Puriﬁed HBcAg was used to
detect anti-capsid antibodies. Puriﬁed HBsAg adw particles (iden-
tical to the injected products) and HBsAg ayw particles (identical to
the antigen produced by the Tg mice) were used to detect anti-
envelope antibodies (Mancini et al., 1993). Antibody titers were
determined by serial end-point dilutions and were deﬁned as the
highest serum dilution that resulted in an absorbance value two
times greater than that of non-immune serum.
Detection and quantiﬁcation of HBsAg were performed by
using a commercial ELISA kit (Monolisa AgHBs Ultra; Bio-Rad,
Marnes la Coquette, France).
ELISPOT assay for determination of T-cell responses
Splenocytes (0.5106 cells/well) were isolated from immunized
mice and incubated with peptide pools (2 mg/ml of each peptide) in
complete a-MEM medium supplemented with 10% FCS in sterile
nitrocellulose MSIP 96-well plates (Millipore, Bedford, MA) coated
with capture antibodies against mouse gamma interferon (IFN-g). In
some experiments, splenocytes were previously depleted of either
CD4þ or CD8þ T-cells by using magnetic beads (Dynal) according
to the manufacturer’s instructions. The IFN-g-coated plates were
incubated at 37 1C for 18 h before scoring the number of spots with
a Bioreader 4000 counter (Biosys). Splenocytes from non-immu-
nized mice and cells in culture medium alone were used as negative
controls to determine background levels. Each cell population was
titrated in triplicate. The response was considered positive if the
median number of spots in triplicate wells was at least twice that
observed in control wells containing medium, and if at least ten
IFN-g-secreting cells per million splenocytes were detected.
Flow cytometry
The cell surface expression of HLA-A2 and HLA-DR1 molecules
was measured on splenocytes or B220þ-enriched B-cells using PE-
conjugated anti-HLA-A2 and APC-conjugated anti-HLA-DR mono-
clonal antibodies, respectively. For intracellular cytokine detection,
freshly isolated splenocytes (1106 cells) were incubated for 1 h
either with medium alone or with peptide pools. Thereafter,
brefeldin A (Sigma-Aldrich) was added to a ﬁnal concentration of
2 mg/ml and the cultures were incubated overnight at 37 1C. Cells
were harvested, washed, and surface-stained with anti-CD3-, anti-
CD4- and anti-CD8-conjugated monoclonal antibodies. Surface-
stained cells were ﬁxed with 2% paraformaldehyde in PBS. Fixed
cells were resuspended in permeabilization buffer (PBS, 1% BSA,
0.05% saponin, and 0.01% sodium azide) and incubated with PE-
conjugated anti-IFN-g mAb for 30 min at 4 1C and washed twice in
permeabilization buffer. Stained cells were resuspended in PBS/1%w/v BSA supplemented with 0.01% w/v sodium azide. All antibodies
were purchased from BD Biosciences. Cells were acquired on
FACSCanto (BD Biosciences) and frequencies were determined by
ﬂow cytometry analyses using Flowjo software (Tree Star).
Statistical analysis
Data were expressed as means7SEM. Nonparametric unpaired
comparisons were performed using the Mann-Whitney U test. For
multiple comparisons of HBsAg concentrations before and after
immunization, the Friedman test followed by Dunn’s post-test were
used. The signiﬁcance level a was set 5%. Statistical analysis was
carried out using Graphpad Prism 5 software. Values of po0.05
were considered signiﬁcant.References
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